Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931682 · ClinicalTrials.gov registry record
Observational Study of Males With Creatine Transporter Deficiency
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 50
- Enrollment target
NCT02931682 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 50 participants.
The verdict
NCT02931682 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the CTD population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-12 |
| Est. Completion | 2022-10-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02931682
The ClinicalTrials.gov registry entry for NCT02931682 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02931682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02931682 about?
NCT02931682 is a clinical study titled "Observational Study of Males With Creatine Transporter Deficiency". The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the CTD population.
What is the current status of trial NCT02931682?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2016-12. Estimated completion is 2022-10-24.
Who is sponsoring clinical trial NCT02931682?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.